Shows
The Swiss ConnectionHow Michael Hall’s TOR Discovery Reframed Longevity ScienceSend us a textWe trace how a soil-derived drug led to the discovery of mTOR, why growth control sits at the core of aging biology, and where evidence ends for humans. Michael Hall’s quiet breakthroughs explain fasting, autophagy, and rapamycin without the hype.To read more about this topic and for more science stories, visit our website swisinfo.ch. You can help other people to find our podcast by leaving us a five-star review.Journalist: Jessica Davis PlüssHost: Jo FahyAudio editor/video journalist: Michele And...
2025-11-2518 minThe Swiss ConnectionBig Pharma steps up race for AI-discovered drugsSend us a textWhat if the most valuable drug candidates aren’t found but designed on demand? We follow a chemist’s journey from a pencil-and-paper notebook to generative algorithms that propose novel, IP-free molecules tailored to specific targets, and we open the door to how Swiss pharma is rebuilding discovery around AI.To read more about this topic and for more science stories, visit our website swisinfo.ch. You can help other people to find our podcast by leaving us a five-star review.Journalist: Jessica Davis Plüss
2025-11-1816 minThe Swiss ConnectionWomen’s Health Meets Drug Design and Medical ResearchSend us a textWe trace how sex and gender shape drug development, from male-heavy mouse studies to the split results in Lecanemab’s Alzheimer’s trial. Experts explain why regulators should keep approvals moving while demanding smarter design, better reporting, and post-approval answers. For more science stories, visit our website swisinfo.ch, and you can help other people to find our podcast by leaving us a five-star review.Journalist: Jessica Davis PlüssHost: Jo FahyAudio editor/video journalist: Michele AndinaDistribution and Marketing: Xin Zhang...
2025-11-1118 minThe Swiss ConnectionCracking the Alzheimer’s CodeSend us a textAlzheimer’s disease is more than age-related memory loss—it’s a serious brain disorder. In this episode of the Swiss Connection Science podcast, Swissinfo healthcare reporter Jessica Davis Pluess explores the science, hope, and controversy surrounding new Alzheimer’s drugs like Leqembi and Kisunla. With billions invested and global regulatory decisions diverging, what do these treatments mean for patients and healthcare systems? Visit SWI swissinfo.ch for more on this topic and a video on this story. Please come to SWI swissinfo.ch for more of our science stories from Switzerla...
2025-11-0421 minThe Swiss ConnectionSwiss Longevity clinics: modern-day snake oil or the key to healthy ageing?Send us a textThe search for the elixir of life has been going on since time immemorial – and Switzerland has played a key role. Although scientists have yet to come up with a winning formula, the Alpine nation has a booming market for treatments, pills and gadgets that claim to slow ageing and help us live healthier, longer lives.Visit SWI swissinfo.ch for more on this topic and a video on this story. Please come to SWI swissinfo.ch for more of our science stories from Switzerland.Jounalist: Jessica Davis Plüss
2025-10-2821 minThe Swiss ConnectionWhy Are leading Swiss Pharmaceutical Companies Investing in Slovenia?Send us a textPharmaceutical giant Novartis invested billions in Slovenia, helping turn the country into a global player in generic drug production. Now, as cheap Asian competitors increasingly dominate the market, Swiss drug companies see the tiny Balkan nation playing a key role in their shift to more complex, expensive medicines.Articles and videos on Switzerland's investment in Slovenia are available on swissinfo.ch. For other science stories from Switzerland please go to www.swissinfo.ch/science.Journalist: Jessica Davis Plüss Host: Jo FahyAudio editor/video journalist: Célin...
2024-04-2316 min